• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MLTX

    MoonLake Immunotherapeutics

    Subscribe to $MLTX
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: https://www.moonlaketx.com

    Recent Analyst Ratings for MoonLake Immunotherapeutics

    DatePrice TargetRatingAnalyst
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$67.00Outperform
    RBC Capital Mkts
    1/17/2025$62.00 → $82.00Neutral → Buy
    Goldman
    11/5/2024$92.00 → $73.00Outperform
    Wedbush
    8/26/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024$104.00Outperform
    Oppenheimer
    4/2/2024$62.00Neutral
    Goldman
    2/15/2024$77.00Outperform
    Wolfe Research
    12/8/2023$72.00Buy
    Citigroup
    11/2/2023$74.00Buy
    Stifel
    See more ratings

    MoonLake Immunotherapeutics Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MoonLake Immunotherapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded MoonLake Immunotherapeutics from Peer Perform to Outperform and set a new price target of $61.00

      5/19/25 8:47:20 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on MoonLake Immunotherapeutics with a new price target

      RBC Capital Mkts initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $67.00

      3/18/25 7:53:47 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics upgraded by Goldman with a new price target

      Goldman upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $82.00 from $62.00 previously

      1/17/25 7:44:04 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on MoonLake Immunotherapeutics with a new price target

      Wedbush resumed coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $73.00 from $92.00 previously

      11/5/24 6:22:06 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics downgraded by Wolfe Research

      Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Peer Perform

      8/26/24 7:38:32 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on MoonLake Immunotherapeutics with a new price target

      Oppenheimer initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $104.00

      6/25/24 7:58:25 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on MoonLake Immunotherapeutics with a new price target

      Goldman initiated coverage of MoonLake Immunotherapeutics with a rating of Neutral and set a new price target of $62.00

      4/2/24 7:34:09 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on MoonLake Immunotherapeutics with a new price target

      Wolfe Research initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $77.00

      2/15/24 6:41:21 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on MoonLake Immunotherapeutics with a new price target

      Citigroup initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $72.00

      12/8/23 7:51:05 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on MoonLake Immunotherapeutics with a new price target

      Stifel initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $74.00

      11/2/23 6:47:18 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care